{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:08:30Z","timestamp":1779883710524,"version":"3.53.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009053","name":"The Wellcome Trust DBT India Alliance","doi-asserted-by":"crossref","award":["IA\/M\/12\/1\/500261"],"award-info":[{"award-number":["IA\/M\/12\/1\/500261"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009053","name":"The Wellcome Trust DBT India Alliance","doi-asserted-by":"crossref","award":["IA\/CPHE\/18\/1\/503940"],"award-info":[{"award-number":["IA\/CPHE\/18\/1\/503940"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012913","name":"Tata Consultancy Services","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012913","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gennova Biopharmaceuticals"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                      asparaginases (EcASNase) available for the treatment of children with acute lymphoblastic leukemia are largely of suboptimal quality in low-middle income countries and contribute to inferior outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The pharmacokinetics, activity, and immunogenicity of a native (EcASNase) and a PEGylated ASNase (PEG-EcASNase) were analyzed. Biogeneric EcASNase (10,000 IU\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) was administered intramuscularly every 72 hours (cohort 1, 76 patients) or every 48 hours (cohort 2, 69 patients). Cohort 3 (176 patients) received a PEG-EcASNase biogeneric (1000 IU\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) intramuscularly every 14 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In cohort 1, 69% of trough induction samples were suboptimal (&lt;100 IU\/L). Cohort 2 achieved a median trough activity &gt;600 IU\/L during induction, with no suboptimal activity. The median trough activity during induction in cohort 3 was 467 IU\/L, with suboptimal activity observed in 7%\u201316%. Patients receiving 1 induction PEG-EcASNase dose had 8-fold higher odds of suboptimal activity postinduction. Hypersensitivity was higher with EcASNase (12% versus 5%) and pancreatitis, more often with PEG-EcASNAse (5% versus 1%). Antidrug antibodies were strongly associated with silent inactivation and hypersensitivity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Pharmacological monitoring enabled optimization of EcASNase dosing, detection of silent PEG-EcASNase inactivation, and identification of induction dosing intensity as a determinant of sustained activity for generic ASNase products marketed in low-middle income countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001473","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:00:13Z","timestamp":1779883213000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Biogeneric Native and Polyethylene Glycol\u2013conjugated Escherichia coli Asparaginases for Treating Children with Acute Lymphoblastic Leukemia"],"prefix":"10.1097","author":[{"given":"Neerajana","family":"Datta","sequence":"first","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishwaranjan","family":"Jana","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijani","family":"Goswami","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annwesha","family":"Roy","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samik","family":"Samaddar","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhajit","family":"Kundu","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manash P.","family":"Gogoi","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bony","family":"Dasgupta","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trina","family":"Dutta","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandana","family":"Das","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaskar","family":"Saha","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"},{"name":"Paediatric Haematology Oncology, Tata Medical Center, Kolkata, India; and"},{"name":"Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmeet","family":"Sidhu","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6769-3847","authenticated-orcid":false,"given":"Shekhar","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India;"},{"name":"Paediatric Haematology Oncology, Tata Medical Center, Kolkata, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20260527","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol."},{"key":"R2-20260527","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2020006583","article-title":"Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia","volume":"137","author":"Gottschalk H\u00f8jfeldt","year":"2021","journal-title":"Blood"},{"key":"R3-20260527","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/bcp.14216","article-title":"A comparison of asparaginase activity in generic formulations of E. coli derived L-asparaginase: in-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia","volume":"86","author":"Sankaran","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"R4-20260527","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(18)30584-9","article-title":"Monitoring asparaginase activity in middle-income countries","volume":"19","author":"Cecconello","year":"2018","journal-title":"Lancet Oncol."},{"key":"R5-20260527","doi-asserted-by":"crossref","first-page":"e29046","DOI":"10.1002\/pbc.29046","article-title":"Unsatisfactory quality of E. coli asparaginase biogenerics in India: implications for clinical outcomes in acute lymphoblastic leukaemia","volume":"68","author":"Sidhu","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R6-20260527","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bjh.17494","article-title":"Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study","volume":"194","author":"Michalowski","year":"2021","journal-title":"Br J Haematol."},{"key":"R7-20260527","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13063-022-06033-1","article-title":"Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India","volume":"23","author":"Das","year":"2022","journal-title":"Trials"},{"key":"R8-20260527","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/GO.20.00113","article-title":"Randomized, parallel group, open-label bioequivalence trial of intramuscular pegaspargase in patients with relapsed acute lymphoblastic leukemia","volume":"6","author":"Nookala Krishnamurthy","year":"2020","journal-title":"JCO Glob Oncol."},{"key":"R9-20260527","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/08880018.2018.1538277","article-title":"Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity","volume":"35","author":"Vyas","year":"2018","journal-title":"Pediatr Hematol Oncol."},{"key":"R10-20260527","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol."},{"key":"R11-20260527","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"key":"R12-20260527","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjh.18158","article-title":"Activity and toxicity of intramuscular 1000 iu\/m(2) polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials","volume":"198","author":"Sidhu","year":"2022","journal-title":"Br J Haematol."},{"key":"R13-20260527","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"key":"R14-20260527","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"key":"R15-20260527","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/sj.leu.2401162","article-title":"Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia","volume":"12","author":"Woo","year":"1998","journal-title":"Leukemia"},{"key":"R16-20260527","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjh.12733","article-title":"Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol","volume":"165","author":"Raja","year":"2014","journal-title":"Br J Haematol."},{"key":"R17-20260527","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3324\/haematol.2014.109413","article-title":"The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia","volume":"99","author":"Tong","year":"2014","journal-title":"Haematologica"},{"key":"R18-20260527","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/bjh.19605","article-title":"The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia","volume":"205","author":"Chen","year":"2024","journal-title":"Br J Haematol."},{"key":"R19-20260527","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr Blood Cancer."},{"key":"R20-20260527","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2015.64.5812","article-title":"Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol."},{"key":"R21-20260527","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/MCG.0000000000000827","article-title":"Risk factors for asparaginase-associated pancreatitis: a systematic review","volume":"51","author":"Oparaji","year":"2017","journal-title":"J Clin Gastroenterol."},{"key":"R22-20260527","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1208\/s12248-021-00649-y","article-title":"Anti-drug antibody validation testing and reporting harmonization","volume":"24","author":"Myler","year":"2021","journal-title":"AAPS J."},{"key":"R23-20260527","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin Exp Immunol."},{"key":"R24-20260527","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1008368916800","article-title":"L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure","volume":"11","author":"Rizzari","year":"2000","journal-title":"Ann Oncol."},{"key":"R25-20260527","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/bloodadvances.2021005631","article-title":"Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study","volume":"6","author":"Lynggaard","year":"2022","journal-title":"Blood Adv."},{"key":"R27-20260527","doi-asserted-by":"crossref","first-page":"100593","DOI":"10.1016\/j.lansea.2025.100593","article-title":"Risk stratified treatment for childhood acute lymphoblastic leukaemia: a multicentre observational study from India","volume":"37","author":"Gogoi","year":"2025","journal-title":"Lancet Reg Health Southeast Asia."},{"key":"R28-20260527","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.23.01797","article-title":"Continuous PEGasparaginase dosing reduces hypersensitivity reactions in pediatric ALL: a Dutch Childhood Oncology Group ALL11 randomized trial","volume":"42","author":"van der Sluis","year":"2024","journal-title":"J Clin Oncol."},{"key":"R29-20260527","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32A","author":"Boos","year":"1996","journal-title":"Eur J Cancer."},{"key":"R30-20260527","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized asparaginase dosing in childhood acute lymphoblastic leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J Clin Oncol."},{"key":"R31-20260527","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000547506","article-title":"Global challenges in paediatric acute lymphoblastic leukaemia","volume":"149","author":"Krishnan","year":"2026","journal-title":"Acta Haematol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:00:21Z","timestamp":1779883221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001473","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"2025-12-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}